Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 5;13:1010105. doi: 10.3389/fimmu.2022.1010105

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Oliveira, Ruiz, Machado, Magawa, Daher, Urbanski, Schmitz, Arcuri, Ferreira, Sasahara, de Medeiros, Júnior, Durigon, Boscardin, Rosa, Schechtman, Nakaya, Cunha-Neto, Gadermaier, Kalil, Coelho and Santos

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

(A) Heatmap representing the magnitude of recognition of SARS-CoV-2 RBD peptides tested for IgG and IgA reactivity using a peptide microarray (columns: ordered by the primary structure sequence) for all convalescents (rows: grouped by antibody isotype and level of neutralizing activity tested in the same samples, and clustered using median values within each group). Highlighted is peptide P44 (S_415-429) and its respective amino acid sequence. High: individuals displaying serum with high neutralizing activity (≥1:160), Low: individuals displaying serum with low neutralizing activity (<1:160). MFI: mean fluorescence intensity. (B) Number of peptides recognized per individual considering high and low VNT for IgG and IgA (C, D) Selected immunodominant peptides recognized by IgG (P12, P14, P18, P30, P44, P50 and P66) and IgA (P6, P12, P14, P18, P30, P44 and P66), of at least 30% of the individuals in the cohort (n=71) are represented with their total percentage of recognition and neutralization titers ranges. P6: peptide 6 (S_353-367), P12: peptide 12 (S_365-379), P14: peptide 14 (S_370-384) and P18: peptide 18 (S_378-392), P30: peptide 30 (S_397-401), P44: peptide 44 (S_415-429), P50: peptide 50 (S_427-441) and P66: peptide 66 (S_459-473).